Ujin Pharma Ltd IPO

Established sourcing network and supply chain capabilities supporting our distribution operations.

Diversified product portfolio catering to multiple end-use industries.

Established customer relationships across domestic and select international markets.

Expansion into value-added chemical processing through our Subsidiary, SSOPL.

We derive a substantial portion of our revenue from operations from our distribution business. Revenue from our distribution business aggregated to Rs.14,441.28 million, Rs.16,220.00 million, Rs.14,787.89 million and Rs.14,257.61 million for the nine-month period ended December 31, 2025 and Fiscals 2025, 2024 and 2023, respectively, representing 95.65%, 99.82%, 100.00% and 100.00% of sale of products, classified by business vertical, for the respective periods. Any adverse developments affecting our distribution business, including reduction in demand, pricing pressures, supply disruptions, inability to source products on commercially acceptable terms or inability to maintain supplier and customer relationships, may materially and adversely affect our business, financial condition, results of operations, cash flows and prospects.

We import chemical products from international markets, with purchases from international suppliers aggregating to Rs.3,976.60 million, Rs.4,140.12 million, Rs.4,238.33 million and Rs.4,625.81 million for the nine-month period ended December 31, 2025 and Fiscals 2025, 2024 and 2023, respectively, representing 26.56%, 26.84%, 30.14% and 33.61% of our total purchases for the respective periods. Any disruption in imports, including due to geopolitical tensions involving the Middle East, the United States and Iran, risks relating to the Strait of Hormuz, the Russia-Ukraine conflict, sanctions, shipping disruptions, increase in freight costs, foreign exchange volatility or adverse changes in import regulations, may materially and adversely affect our business, financial condition, results of operations, cash flows and prospects.

Our top 10 suppliers contributed Rs.6,933.09 million, Rs.7,418.98 million, Rs.5,670.21 million and Rs.6,237.05 million to our total purchases for the nine-month period ended December 31, 2025 and Fiscals 2025, 2024 and 2023, respectively, representing 46.13%, 48.10%, 40.32% and 45.32% of our total purchases for the respective periods. Any inability to procure products from our significant suppliers on commercially acceptable terms, or at all, may materially and adversely affect our business, financial condition, results of operations, cash flows and prospects.

A substantial portion of our revenue from sale of products is generated through indirect sales to thirdparty traders and distributors. Revenue from indirect sales aggregated to Rs.10,191.50 million, Rs.10,974.48 million, Rs.10,892.85 million and Rs.8,911.61 million for the nine-month period ended December 31, 2025 and Fiscals 2025, 2024 and 2023, respectively, representing 67.50%, 67.54%, 73.66% and 62.50% of our revenue from sale of products for the respective periods. Any inability to maintain relationships with such third-party traders and distributors, or any inability to accurately determine the end-use industry of products sold through them, may adversely affect our business, financial condition, results of operations, cash flows and prospects.